Nintedanib as Infigratinib replacement for FGFR3 block in heightmaxxing

[mememanw24]

Nintedanib is available in my country and hits FGFR3 while infigratinib is basically impossible to get.


Infigratinib has real achondroplasia trial data showing increased growth velocity by inhibiting FGFR3 over-signaling.



Since nintedanib also inhibits FGFR3 (though broader/weaker), could it give similar bone growth benefits in normal teens with open plates?


Or is the FGFR3 affinity too low at safe doses (100–200 mg/day cancer dose) and it’s cope compared to infigratinib?

 

[Thatfish]

Infigratinib would be better since Nintedanib isn’t usable at a feasible dosage where it’ll effectively inhibit FGFR3 enough whilst not retarding other growth pathways or leading to serious adverse side effects; I’m pretty sure it’s sourceable to most countries as well except for Antarctica or Iran or something

 

[ascendtocl122]

good greys

 

[Zorbital]

View attachment 4756701Infigratinib would be better since Nintedanib isn’t usable at a feasible dosage where it’ll effectively inhibit FGFR3 enough whilst not retarding other growth pathways or leading to serious adverse side effects; I’m pretty sure it’s sourceable to most countries as well except for Antarctica or Iran or something

where du source Infigratinib ?